Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method

International Journal of Antimicrobial Agents

Volumn 21, Issue 3, 2003, Pages 229-233

  Lass Flörl, Cornelia ^a   Speth, C ^a   Kofler, G ^a   Dierch, M P ^a   Gunsilius, E ^b   Wurzner R ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Aspergillus hyphae; MFC; MIC

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; INOCULATION; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE; TIME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; HUMANS; ITRACONAZOLE; PYRIMIDINES; TRIAZOLES;

EID: 0037334425     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00189-9     Document Type: Article

References (20)

1. Denning D.W. Invasive aspergillosis in immunocompromised patients. Curr. Opin. Infect. Dis. 9:1994;456-462.
2. Denning D.W. Invasive aspergillosis. Clin. Infect. Dis. 26:1998;781-805.
3. Denning D.W., Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev. Infect. Dis. 12:1990;1147-1201. published erratum appears in Rev. Infect. Dis. 1991 March-April;13(2):345.
4. Gerson L.S., Talbot G.H., Hurwitz S., Strom B.L., Lusk E.J., Cassileth P.A. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann. Intern. Med. 100:1984;345-351.
5. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:1998;198-202.
6. Espinel-Ingroff A., Dawson K., Pfaller M., et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39:1995;314-319.
7. Rex J., Pfaller M., Rinaldi M., Polak A., Galgani N.J. Antifungal susceptibility testing. Clin. Microb. Rev. 6:1993;367-381.
8. Hay R.J. The prevention of invasive aspergillosis - a realistic goal. J. Antimicrob. Chemother. 32:1993;515-517.
9. Lass-Flörl C., Kofler G., Kropshofer G., et al. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J. Antimicrob. Chemother. 42:1998;497-502.
10. Neumeister B., Hartmann W., Oetihinger M., Heymer B., Marre R. A fatal infection with Alternaria alternata and Aspergillus terreus in a child with agranulocytosis of unknown origin. Mycoses. 37:1994;181-185.
11. Peterson P.K., McGlave P., Ramsay N., Rhame F., Cohen E., Perry G.S. A prospective study of infectious diseases following bone marrow transplantation: emergence of Aspergillus and cytomegalovirus as the major causes mortality. Am. J. Infect. Cont. 4:1998;81-89.
12. Prentice A.G., Hannn M., Herbrecht R., et al. A randomized comparision of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 98:1997;711-718.
13. Lass-Flörl C., Nagl M., Speth C., Ulmer H., Dierich M.P., Würzner R. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob. Agents Chemother. 45:2001;124-128.
14. Brook I. Inoculum effect. Rev. Infect. Dis. 11:1989;361-368.
15. Stratton C. Bactericidal testing. Infect. Dis. Clin. North Am. 7:1993;445-459.
16. Gehrt A., Peter J., Pizzo P., Walsh T. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J. Clin. Microbiol. 33:1995;1302-1307.
17. Bossche H.V., Marichal P., Geerts H., Janssen P.A. The molecular basis for itraconazole's activity against Aspergillus fumigatus. Vanden Bossche H. Aspergillus and aspergillosis. 1988;171-197 Plenum Publishing Corporation, New York.
18. Polak A. Mode of action studies. Ryley J.F. Handbook of experimental pharmacology. Chemotherapy of fungal diseases. 1990;153-182 Springer, Berlin.
19. Wong-Beringer A., Jacobs A., Guglielmo J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27:1998;603-618.
20. Sokol-Anderson M., Brajtburg J., Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J. Infect. Dis. 154:1986;76-83.